How to Cite
Abstract
Health Technology Assessment (HTA) studies subsidize decisions regarding the rational use of health technologies. Finding a balance between the sustainability of health systems, and proper access and use of technology, is a challenge and requires the use of consistent tools. In this paper we analyzed the general characteristics of the agencies or institutions responsible for HTA in Brazil, Australia, Canada and England and we carried out a comparative case study to understand the incorporation of protease inhibitors telaprevir and boceprevir for the treatment of chronic hepatitis C in these countries. For that purpose, we used electronic published reports found on the websites of those HTA agencies regarding telaprevir and boceprevir in 2013. Compared to other agencies, the Brazilian Commission (CONITEC) unlike the others, accepted the submission and published a single report for both drugs; the HTA model was homogeneous across countries. There were differences in the eligibility criteria and target population, despite the fact of drug approval; the price charged in Brazil was the lowest; the Brazilian CONITEC also set the criteria for healthcare using the drugs and for clinical protocols and therapeutic guidelines. Keywords: BiomedicalTechnology; Hepatitis C; ProteaseInhibitorsReferences
Kristensen FB, Lampe K, Chase DL, Lee-Robin SH, Wild C, Moharra M, et al. Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA. Int J Technol Assess Health Care. 2009; 25 Suppl 2:1–8.
Cuyler AJ. Four issues in cost-efectiveness analysis and health technology assessment: a view from the touch-line. In: Llano Señaris JE, Campillo-Artero C. Health Technology Assessment and Health Policy Today: a multifaceted view of the unstable crossroads. Switlzerlad: Springer International Publishing; 2015. p. 77-94.
Silva EN, Silva MT, Elias FTS. Sistemas de Saúde e Avaliação de Tecnologias em Saúde. Em: Nita ME, Secoli SR, Nobre MRC, editores. Avaliação de Tecnologias em Saúde: evidência clínica, análise econômica e análise de decisão. Porto Alegre: Artmed; 2010. p. 419–32.
Polanczyk CA, Vanni T, Kuchenbecker RS. Avaliação de Tecnologias em Saúde no Brasil e no Contexto Intenacional. Em: Nita ME, Secoli SR, Nobre MRC, editores. Avaliação de Tecnologias em Saúde: evidência clínica, análise econômica e análise de decisão. Artmed; 2010. p. 433–49.
Hailey DM. Health technology assessment in Canada: diversity and evolution. Med J Aust. 2007; 187(5): 286.
Hailey D. The history of health technology assessment in Australia. Int J Technol Assess Health Care. 2009; 25(S1): 61.
Morihara D, Watanabe H, Takata K, Iwashita H, Tsuchiya N, Kunimoto H, et al. Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rates. Eur J Gastroenterol Hepatol. 2015; 27(1): 55-64.
Hutchison JG, Manns MP, Muir JA, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Eng J Med 2010; 362: 1292-1303.
Wilsdon T, Fiz E, Haderi A. A comparative analysis of the role and impact of Health Technology Assessment 2013 (Final Report). [Internet] Brussels: Charles River Associate. May 2014 [citado em 2015 Feb 01]. Disponível em: http://www.efpia.eu/uploads/documents/cra-comparative-analysis.pdf
National Institute for Health and Care Excellence. Telaprevir for the treatment of genotype 1 chronic hepatitis C (technology appraisal guidance TA 252). Londres: April 2012 [citado em 2015 Feb 01]. Disponível em: https://www.nice.org.uk/guidance/ta252
National Institute for Health and Care Excellence. Boceprevir for the treatment of genotype 1 chronic hepatitis C (technology appraisal guidance TA 253). Londres: April 2012 [citado em 2015 Feb 01]. Disponível em: https://www.nice.org.uk/guidance/ta253
Canadian Agency for Drugs and Technology in Health. CDEC Final Recommendation: Telaprevir. Toronto: June 2013 [citado em 2015 Feb 01]. Disponível em: http://www.cadth.ca/media/cdr/complete/cdr_complete_Incivek%20RFA-SR0311-June-14-13.pdf
Canadian Agency for Drugs and Technology in Health. CDEC Final Recommendation: Boceprevir. Toronto: June 2013 [citado em 2015 Feb 01]. Disponível em: http://www.cadth.ca/media/cdr/complete/cdr_complete_SF0312-Victrelis_RFA_June-14-13.pdf
Pharmaceutical Benefits Advisory Committee (PBAC). Public Summary Document: Telaprevir. Sydney: June 2012 [citado em 2015 Feb 01]. Disponível em: http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2012-07/telaprevir.pdf
Pharmaceutical Benefits Advisory Committee (PBAC). Public Summary Document: Boceprevir. Sydney: June 2012 [citado em 2015 Feb 01]. Disponível em: http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2012-07/boceprevir.pdf
Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Inibidores de protease (Boceprevir e Telaprevir) para o tratamento da hepatite crônica C. Brasília: July 2012 [citado em 2015 Feb 01]. Disponível em: http://conitec.gov.br/images/Relatorios/2012/Boceprevir_Telaprevir_final.pdf
Krauss-Silva L. Avaliação tecnológica em saúde: questões metodológicas e operacionais Technology assessment in health care: methodological and operational questions. Cad Saúde Pública. 2004;20(Sup 2): S199–S207.
Brasil, Secretaria de Ciência T e IE, Departamento de Ciência e Tecnologia. Política nacional de gestão de tecnologias em saúde. Brasília, DF: Ministério da Saúde; 2010.